According to Future Market Insights (FMI) analysis in a recent market survey, the global spasticity treatment market was valued at US$ 12.2 Billion in 2022 and is set to reach US$ 28.4 Billion by 2033.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 12.2 Billion |
| Market Value 2023 | US$ 13.1 Billion |
| Market Value 2033 | US$ 28.4 Billion |
| CAGR 2023 to 2033 | 8.1% |
| Share of Top 5 Countries | 54.0% |
| Key Players | Medtronic Plc; Piramal Enterprises Ltd.; AbbVie, Inc. (Allergan); Ipsen Pharma; F. Hoffmann-La Roche Ltd; GlaxoSmithKline plc; Pfizer Inc.; Elite Pharmaceuticals Inc.; Orient Pharma; Acorda Therapeutics, Inc.; Sun Pharmaceutical Industries Ltd; Novartis AG (Alcon); Teva Pharmaceutical Industries Ltd; Zydus Cadila Healthcare Ltd.; Beximco Pharmaceuticals Ltd; Merz Pharma; Thought Technology Ltd.; UltraCare PRO; Invacare Corporation; ATI Physical Therapy; P.T. Services Rehabilitation, Inc.; Banner Health. |
Spasticity is one of many clinical traits or motor behavior that can appear following injury to the area of the brain or spinal cord that regulates voluntary movements. Upper motor neuron syndrome is the term used to describe these symptoms taken together.
One of the key factors promoting the growth of the spasticity treatment market is the rising prevalence of neuro-musculoskeletal disorders. Spasticity is becoming more common as chronic neuro-musculoskeletal illnesses become more common on a global scale.
The high prevalence of these illnesses worldwide is a result of an increase in slips, accidents, assaults, and other incidents. A diagnosis of spasticity was made in more than 50% to 60% of these cases. The global market thus benefits from the rising prevalence of various chronic disorders due to the close association between the aforementioned chronic conditions and spasticity. This rising incidence will drive market expansion over the forecast period.
Overall, the adoption of spasticity treatment in healthcare facilities, which will boost the market in the coming years.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Sales of the global market grew at a CAGR of 5.4% between 2012 and 2022. Spasticity treatment market contributes 29.6% revenue share to the global neurodegenerative disease treatment market value at US$ 41.2 Billion in 2022.
The ageing population is one of the primary factors fueling the market for spasticity treatments.
Age-related changes in the brain, traumas like stroke or traumatic brain damage, addiction, and diseases like multiple sclerosis (MS), stroke, and brain tumours, among others, can all have a substantial impact on brain health, which will increase the prevalence of spasticity and its related indications, which will boost the market for spasticity treatments.
Advanced procurement operations provide businesses and manufacturers with chances to develop and expand their clientele to buyers and suppliers that collaborate to create cutting-edge products that increase sales and profits for all parties. By implementing several techniques into their processes, they adopt an integrated approach to creating new goods and procedures.
Different key strategies such as new product launches, acquisitions, collaborations, and expansion are being used by companies and different manufacturers for the advancement and development of new products and therapies.
Considering this, FMI expects the global market to grow at a CAGR of 8.1% through the forecasted years.
Cognitive knowledge and evaluation of everyday things and issues is one of the most important indicators of a person's mental health and ability to think and act in life-or-death situations.
The brain is a sophisticated organ that has a significant impact on one's overall health and well-being. Brain health can be significantly impacted by ageing-related changes in the brain and traumas like stroke or traumatic brain injury. While certain factors that affect brain health cannot be avoided, there are other lifestyle changes that can be beneficial.
Since they improve brain glucose metabolism and reduce the risk of mental disorders, improved brain and mental fitness is becoming more and more in demand, opening up new treatment options for spasticity.
Increased testing of combination therapies in patients will pave the way for new drug discoveries and treatment options, ultimately leading to the introduction of new products into the market.
Principal Consultant
For the spasticity treatment process, there is a requirement of skilled specialists such as physiatrists, neurologists, rehabilitation nurses, physical and occupational therapists, speech and language pathologists, psychologists, social workers, recreational therapists, etc.
The non-availability and limited number of such well-trained specialists can have an adverse impact on the treatment of patients with spasticity and also lower the growth of the organizations that are involved in the treatment. Due to these factors, the quality of services can get affected, and this will ultimately have a negative impact on the growth of the spasticity treatment market.
The dearth of skilled professionals in these fields can lower the quality of services offered, ultimately affecting the growth of the spasticity treatment market.
These factors are expected to hamper revenue growth of the global market over the forecast period.
The USA market dominated the global market with value of around US$ 3.63 Bilion in 2022 and is expected to register a CAGR of 8.3% during the forecast period.
The high prevalence of spasticity in the United States will accelerate the acceptance of various treatment alternatives.
Due to the high prevalence, more treatments, including over-the-counter products, will experience a high adoption rate among patients. The demand for spasticity treatment will increase due to high prevalence, which will drive the expansion of the market.
Germany dominated the European market for spasticity treatment and accounted for around 22.3% of the regional market share in 2022.
Increasing technological advancements in spasticity treatment therapies in Germany is driving the overall Europe spasticity treatment market.
Virtual reality technology can be used to provide immersive therapy experiences for patients with spasticity. These experiences can help patients to improve their motor skills and reduce spasticity through interactive and engaging activities. This therapy has been found to be effective in reducing spasticity in patients with cerebral palsy, multiple sclerosis, and other neurological conditions.
The safe and successful spasticity treatment therapies in Germany will influence other European countries to also opt for this treatment method, ultimately expanding the overall market.
China is projected to be the most attractive market in the East Asia region, and is expected to grow over a significant CAGR of 7.7% during the forecast duration.
The spasticity treatment market in China is expected to grow significantly in the coming years due to several factors.
One of the main factors driving the growth of the spasticity treatment market in China is the increasing awareness of the condition among the general public and healthcare professionals. As more people become aware of the condition, they are more likely to seek treatment, which is leading to increased demand for treatments for spasticity.
Another factor contributing to the growth of the spasticity treatment market in China is the increasing availability of advanced medical technologies and treatments. China has made significant investments in its healthcare infrastructure, and many new hospitals and clinics have been built in recent years. This has allowed for the introduction of advanced treatments such as botox injections and surgery, which were not widely available in the past.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The treatment segment utilizing drugs, physical therapy, Botulinum toxin, surgical treatment and others treatment options held the major chunk of about 68.4% in global market by the end of 2022.
With advances in medical technology, it has become easier to diagnose spasticity accurately. This has led to more people being diagnosed with the condition, which in turn has increased the demand for treatment. There is now more awareness about spasticity among healthcare providers, patients, and the general public. This has helped to reduce the stigma associated with the condition and encouraged more people to seek treatment.
There have been significant advances in the development of new treatments for spasticity, including medications, physical therapy, and surgical procedures. These treatments can help to reduce spasticity and improve overall quality of life for people with the condition.
The Cerebral Palsy segment held the major chunk of about 14.4% in global market by the end of 2022.
Increased awareness of cerebral palsy and improved diagnostic techniques have led to more accurate diagnosis and reporting of cases, contributing to the observed increase in prevalence. Certain risk factors, such as maternal infections during pregnancy, prematurity, and low birth weight, have become more common in recent years. This has contributed to the increase in the incidence of cerebral palsy and spasticity.
The hospital pharmacies segment accounted for revenue share of 38.3% in the global market at the end of 2022.
Hospital pharmacies offer convenient access to treatment options, with many providing over-the-counter and prescription medications for a range of conditions, including cerebral palsy, multiple sclerosis among others. Patients can typically purchase these treatments without an appointment, making it more convenient for them to manage their condition.
Overall, hospital pharmacies offers a convenient and accessible distribution channel for spasticity treating products, making it the largest channel for these treatments.
The hospitals segment accounted for revenue share of 37.1% in the global market at the end of 2022.
Hospitals typically have access to a wide range of specialized medical professionals, including neurologists, physiatrists, orthopedic surgeons, and physical therapists, who can collaborate to provide comprehensive spasticity treatment.
Overall, hospitals are a leading segment for spasticity treatment because they provide access to specialized medical professionals, advanced diagnostic tools, multimodal treatments, specialized equipment and facilities, and both inpatient and outpatient services.
Key players in the market are focused on increase their product portfolio to strengthen their position in the spasticity treatment market, and also to expand their footprint in emerging markets. The key strategy adopted by manufacturers to gain competitive edge in the market are the pricing strategies, market strategies, technological advancements, regulatory compliance and acquisition of other companies to expand their business.
For instance:
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the spasticity treatment market space, which are available in the full report
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2012 to 2022 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, United Kingdom, France, Italy, Spain, Russia, BENELUX, Nordics, India, Thailand, Indonesia, Malaysia, Philippines, Vietnam, China, Japan, South Korea, Australia, New Zealand, Türkiye, South Africa, North Africa and GCC Countries |
| Key Segments Covered | Diagnosis & Treatment Type, Indication, Distribution Channel, Service Providers, and Region |
| Key Companies Profiled | Medtronic Plc; Piramal Enterprises Ltd.; AbbVie, Inc. (Allergan); Ipsen Pharma; F. Hoffmann-La Roche Ltd; GlaxoSmithKline plc; Pfizer Inc.; Elite Pharmaceuticals Inc.; Orient Pharma; Acorda Therapeutics, Inc.; Sun Pharmaceutical Industries Ltd; Novartis AG (Alcon); Teva Pharmaceutical Industries Ltd; Zydus Cadila Healthcare Ltd.; Beximco Pharmaceuticals Ltd; Merz Pharma; Thought Technology Ltd.; UltraCare PRO; Invacare Corporation; ATI Physical Therapy; P.T. Services Rehabilitation, Inc.; Banner Health |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The global market is valued around US$ 12.2 Billion in 2022.
The global market estimates for 2023 is around US$ 13.1 Billion.
The global market is set to reach US$ 28.4 Billion by the end of 2033, with sales revenue expected to be 8.1% CAGR through 2033.
North America dominated the global market in 2022 with the USA being the leading contributor in the North American region.
Rising demand for improved brain and mental fitness and improving healthcare infrastructure to offer lucrative growth opportunities for the market players to grow.
Cerebral palsy segment dominated the global market in 2022 with 14.4% revenue share and is expected to lead in 2023 as well.
The USA, India, China, Germany and United Kingdom are the top countries that are driving the demand for the spasticity treatment globally.
From 2012 to 2022, the market for spasticity treatment expanded at the rate of 5.4%.
Allergan plc. (AbbVie), F. Hoffmann-La Roche Ltd, Pfizer Inc., Medtronic Plc, GlaxoSmithKline plc, are few key players within the global market.
China is projected to grow with CAGR of 7.7% over the forecast duration.
1. Global Market- Executive Summary | Spasticity Treatment Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply-Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusion and Exclusion 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Indication Innovation / Development Trends 4. Value Added Insights 4.1. Product Adoption/Usage Analysis, By Region 4.2. Regulatory Scenario 4.3. Data on Insurance Coverage 4.4. Cost of treatment by Key Countries 4.5. Annual Patient Volume of Indications for Key Countries 4.5.1. Cerebral Palsy 4.5.2. Multiple Sclerosis 4.5.3. Amyotrophic Lateral Sclerosis 4.5.4. Hereditary Spastic Paraplegias 4.5.5. Periventricular Leukomalacia 4.5.6. Metabolic Diseases 4.5.7. Traumatic Brain Injury 4.5.8. Spinal Cord Injury 4.5.9. Stroke 4.5.10. Multiple System Atrophy 4.5.11. Stiff-Person Syndrome 4.5.12. Infectious Transvers Myelitis 4.5.13. Encephalopathy 4.5.14. Brain Tumor 4.5.15. Krabbe Disease 4.5.16. Multiple System Atrophy 4.5.17. Johns Hopkins Disease 4.6. Distribution Channel Information 4.7. PESTLE Analysis 4.8. Key Promotional Strategies by Manufacturers 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Expenditure Market Outlook 5.1.3. Global Pharmaceutical Market Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Strategic Developments by Key Players 5.2.2. Technological Advancements 5.2.3. Top Companies Historical Growth 5.2.4. Research and Development Activities 5.2.5. Adoption of in Healthcare Facilities 5.2.6. Cost of Products 5.2.7. Increasing Prevalence of Spasticity Related Indications 5.2.8. GDP Growth 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis Analysis 6.1. COVID-19 and Impact Analysis 6.1.1. Revenue By Indication 6.1.2. Revenue By Diagnosis & Treatment Type 6.1.3. Revenue By Distribution Channel 6.1.4. Revenue By Service Providers 6.1.5. Revenue By Country 6.2. 2022 Market Scenario 7. Global Market Demand (in Value US$ Million) Analysis 2012 to 2022 and Forecast, 2023 to 2033 7.1. Historical Market Value (US$ Million) Analysis, 2012 to 2022 7.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, by Diagnosis & Treatment Type 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis by Diagnosis & Treatment Type, 2012 to 2022 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Diagnosis & Treatment Type, 2023 to 2033 8.3.1. Diagnosis 8.3.1.1. Inpatient 8.3.1.2. Outpatient 8.3.2. Treatment Type 8.3.2.1. Drug 8.3.2.1.1. Baclofen 8.3.2.1.2. Tizanidine 8.3.2.1.3. Dantrolene sodium 8.3.2.1.4. Diazepam 8.3.2.1.5. Clonazepam 8.3.2.1.6. Gabapentin 8.3.2.1.7. Others 8.3.2.2. Physical Therapy 8.3.2.3. Botulinum injection 8.3.2.4. Surgery Treatment 8.3.2.5. Other Treatment 8.3.3. Devices 8.3.3.1. Reciprocal EMG-Triggered Stimulation 8.3.3.2. Transcutaneous Electrical Nerve Stimulation 8.3.3.3. Bracing and Cuff 8.3.3.4. Leg lifter 8.3.3.5. Cane and Crunches 8.3.3.6. Wheelchair 8.3.3.7. Others 8.4. Market Attractiveness Analysis by Diagnosis & Treatment Type 9. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, by Indication 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis by Indication, 2012 to 2022 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033 9.3.1. Cerebral Palsy 9.3.2. Multiple Sclerosis 9.3.3. Amyotrophic Lateral Sclerosis 9.3.4. Hereditary Spastic Paraplegias 9.3.5. Periventricular Leukomalacia 9.3.6. Metabolic Diseases 9.3.7. Traumatic Brain Injury 9.3.8. Spinal Cord Injury 9.3.9. Stroke 9.3.10. Multiple System Atrophy 9.3.11. Stiff-Person Syndrome 9.3.12. Infectious Transvers Myelitis 9.3.13. Encephalopathy 9.3.14. Brain Tumor 9.3.15. Krabbe Disease 9.3.16. Multiple System Atrophy 9.3.17. Johns Hopkins Disease 9.4. Market Attractiveness Analysis by Indication 10. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Distribution Channel 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2012 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 10.3.1. Hospital Pharmacies 10.3.2. Retail Pharmacies 10.3.3. Drug Stores 10.3.4. Online Pharmacies 10.4. Market Attractiveness Analysis By Distribution Channel 11. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Service Providers 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis By Service Providers, 2012 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Service Providers, 2023 to 2033 11.3.1. Hospitals 11.3.2. Ambulatory Surgical Centers 11.3.3. Home Care Settings 11.3.4. Specialty Clinics 11.3.5. Diagnostic Centers 11.4. Market Attractiveness Analysis By Service Providers 12. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, by Region 12.1. Introduction 12.2. Historical Market Size (US$ Million) Analysis by Region, 2012 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Region, 2023 to 2033 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. South Asia 12.3.5. East Asia 12.3.6. Oceania 12.3.7. Middle East & Africa(MEA) 12.4. Market Attractiveness Analysis by Region 13. North America Market Analysis 2012 to 2022 and Forecast 2023 to 2033 13.1. Introduction 13.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 13.3.1. By Country 13.3.1.1. USA 13.3.1.2. Canada 13.3.2. By Indication 13.3.3. By Diagnosis & Treatment Type 13.3.4. By Distribution Channel 13.3.5. By Service Providers 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Indication 13.4.3. By Diagnosis & Treatment Type 13.4.4. By Distribution Channel 13.4.5. By Service Providers 13.5. Key Market Participants - Intensity Mapping 13.6. Drivers and Restraints - Impact Analysis 13.7. Country Level Analysis & Forecast 13.7.1. USA Market 13.7.1.1. Introduction 13.7.1.2. Market Analysis and Forecast by Market Taxonomy 13.7.1.2.1. By Indication 13.7.1.2.2. By Diagnosis & Treatment Type 13.7.1.2.3. By Distribution Channel 13.7.1.2.4. By Service Providers 13.7.2. Canada Market 13.7.2.1. Introduction 13.7.2.2. Market Analysis and Forecast by Market Taxonomy 13.7.2.2.1. By Indication 13.7.2.2.2. By Diagnosis & Treatment Type 13.7.2.2.3. By Distribution Channel 13.7.2.2.4. By Service Providers 14. Latin America Market Analysis 2012 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast recast by Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. Brazil 14.3.1.2. Mexico 14.3.1.3. Argentina 14.3.1.4. Rest of Latin America 14.3.2. By Indication 14.3.3. By Diagnosis & Treatment Type 14.3.4. By Distribution Channel 14.3.5. By Service Providers 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Indication 14.4.3. By Diagnosis & Treatment Type 14.4.4. By Distribution Channel 14.4.5. By Service Providers 14.5. Key Market Participants - Intensity Mapping 14.6. Drivers and Restraints - Impact Analysis 14.7. Country Level Analysis & Forecast 14.7.1. Brazil Market 14.7.1.1. Introduction 14.7.1.2. Market Analysis and Forecast by Market Taxonomy 14.7.1.2.1. By Indication 14.7.1.2.2. By Diagnosis & Treatment Type 14.7.1.2.3. By Distribution Channel 14.7.1.2.4. By Service Providers 14.7.2. Mexico Market 14.7.2.1. Introduction 14.7.2.2. Market Analysis and Forecast by Market Taxonomy 14.7.2.2.1. By Indication 14.7.2.2.2. By Diagnosis & Treatment Type 14.7.2.2.3. By Distribution Channel 14.7.2.2.4. By Service Providers 14.7.3. Argentina Market 14.7.3.1. Introduction 14.7.3.2. Market Analysis and Forecast by Market Taxonomy 14.7.3.2.1. By Indication 14.7.3.2.2. By Diagnosis & Treatment Type 14.7.3.2.3. By Distribution Channel 14.7.3.2.4. By Service Providers 15. Europe Market Analysis 2012 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2022 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. Italy 15.3.1.3. France 15.3.1.4. United Kingdom 15.3.1.5. Spain 15.3.1.6. BENELUX 15.3.1.7. Nordic Countries 15.3.1.8. Russia 15.3.1.9. Rest of Europe 15.3.2. By Indication 15.3.3. By Diagnosis & Treatment Type 15.3.4. By Distribution Channel 15.3.5. By Service Providers 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Indication 15.4.3. By Diagnosis & Treatment Type 15.4.4. By Distribution Channel 15.4.5. By Service Providers 15.5. Key Market Participants - Intensity Mapping 15.6. Drivers and Restraints - Impact Analysis 15.7. Country Level Analysis & Forecast 15.7.1. Germany Market 15.7.1.1. Introduction 15.7.1.2. Market Analysis and Forecast by Market Taxonomy 15.7.1.2.1. By Indication 15.7.1.2.2. By Diagnosis & Treatment Type 15.7.1.2.3. By Distribution Channel 15.7.1.2.4. By Service Providers 15.7.2. Italy Market 15.7.2.1. Introduction 15.7.2.2. Market Analysis and Forecast by Market Taxonomy 15.7.2.2.1. By Indication 15.7.2.2.2. By Diagnosis & Treatment Type 15.7.2.2.3. By Distribution Channel 15.7.2.2.4. By Service Providers 15.7.3. France Market 15.7.3.1. Introduction 15.7.3.2. Market Analysis and Forecast by Market Taxonomy 15.7.3.2.1. By Indication 15.7.3.2.2. By Diagnosis & Treatment Type 15.7.3.2.3. By Distribution Channel 15.7.3.2.4. By Service Providers 15.7.4. United Kingdom Market 15.7.4.1. Introduction 15.7.4.2. Market Analysis and Forecast by Market Taxonomy 15.7.4.2.1. By Indication 15.7.4.2.2. By Diagnosis & Treatment Type 15.7.4.2.3. By Distribution Channel 15.7.4.2.4. By Service Providers 15.7.5. Spain Market 15.7.5.1. Introduction 15.7.5.2. Market Analysis and Forecast by Market Taxonomy 15.7.5.2.1. By Indication 15.7.5.2.2. By Diagnosis & Treatment Type 15.7.5.2.3. By Distribution Channel 15.7.5.2.4. By Service Providers 15.7.6. BENELUX Market 15.7.6.1. Introduction 15.7.6.2. Market Analysis and Forecast by Market Taxonomy 15.7.6.2.1. By Indication 15.7.6.2.2. By Diagnosis & Treatment Type 15.7.6.2.3. By Distribution Channel 15.7.6.2.4. By Service Providers 15.7.7. Nordic Countries Market 15.7.7.1. Introduction 15.7.7.2. Market Analysis and Forecast by Market Taxonomy 15.7.7.2.1. By Indication 15.7.7.2.2. By Diagnosis & Treatment Type 15.7.7.2.3. By Distribution Channel 15.7.7.2.4. By Service Providers 15.7.8. Russia Market 15.7.8.1. Introduction 15.7.8.2. Market Analysis and Forecast by Market Taxonomy 15.7.8.2.1. By Indication 15.7.8.2.2. By Diagnosis & Treatment Type 15.7.8.2.3. By Distribution Channel 15.7.8.2.4. By Service Providers 16. South Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million)Trend Analysis By Market Taxonomy, 2012 to 2022 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. India 16.3.1.2. Thailand 16.3.1.3. Indonesia 16.3.1.4. Malaysia 16.3.1.5. Philippines 16.3.1.6. Vietnam 16.3.1.7. Rest of South Asia 16.3.2. By Indication 16.3.3. By Diagnosis & Treatment Type 16.3.4. By Distribution Channel 16.3.5. By Service Providers 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Indication 16.4.3. By Diagnosis & Treatment Type 16.4.4. By Distribution Channel 16.4.5. By Service Providers 16.5. Key Market Participants - Intensity Mapping 16.6. Drivers and Restraints - Impact Analysis 16.7. Country Level Analysis & Forecast 16.7.1. India Market 16.7.1.1. Introduction 16.7.1.2. Market Analysis and Forecast by Market Taxonomy 16.7.1.2.1. By Indication 16.7.1.2.2. By Diagnosis & Treatment Type 16.7.1.2.3. By Distribution Channel 16.7.1.2.4. By Service Providers 16.7.2. Thailand Market 16.7.2.1. Introduction 16.7.2.2. Market Analysis and Forecast by Market Taxonomy 16.7.2.2.1. By Indication 16.7.2.2.2. By Diagnosis & Treatment Type 16.7.2.2.3. By Distribution Channel 16.7.2.2.4. By Service Providers 16.7.3. Indonesia Market 16.7.3.1. Introduction 16.7.3.2. Market Analysis and Forecast by Market Taxonomy 16.7.3.2.1. By Indication 16.7.3.2.2. By Diagnosis & Treatment Type 16.7.3.2.3. By Distribution Channel 16.7.3.2.4. By Service Providers 16.7.4. Malaysia Market 16.7.4.1. Introduction 16.7.4.2. Market Analysis and Forecast by Market Taxonomy 16.7.4.2.1. By Indication 16.7.4.2.2. By Diagnosis & Treatment Type 16.7.4.2.3. By Distribution Channel 16.7.4.2.4. By Service Providers 16.7.5. Philippines Market 16.7.5.1. Introduction 16.7.5.2. Market Analysis and Forecast by Market Taxonomy 16.7.5.2.1. By Indication 16.7.5.2.2. By Diagnosis & Treatment Type 16.7.5.2.3. By Distribution Channel 16.7.5.2.4. By Service Providers 16.7.6. Vietnam Market 16.7.6.1. Introduction 16.7.6.2. Market Analysis and Forecast by Market Taxonomy 16.7.6.2.1. By Indication 16.7.6.2.2. By Diagnosis & Treatment Type 16.7.6.2.3. By Distribution Channel 16.7.6.2.4. By Service Providers 17. East Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million)Trend Analysis By Market Taxonomy, 2012 to 2022 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. China 17.3.1.2. Japan 17.3.1.3. South Korea 17.3.2. By Indication 17.3.3. By Diagnosis & Treatment Type 17.3.4. By Distribution Channel 17.3.5. By Service Providers 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Indication 17.4.3. By Diagnosis & Treatment Type 17.4.4. By Distribution Channel 17.4.5. By Service Providers 17.5. Key Market Participants - Intensity Mapping 17.6. Drivers and Restraints - Impact Analysis 17.7. Country Level Analysis & Forecast 17.7.1. China Market 17.7.1.1. Introduction 17.7.1.2. Market Analysis and Forecast by Market Taxonomy 17.7.1.2.1. By Indication 17.7.1.2.2. By Diagnosis & Treatment Type 17.7.1.2.3. By Distribution Channel 17.7.1.2.4. By Service Providers 17.7.2. Japan Market 17.7.2.1. Introduction 17.7.2.2. Market Analysis and Forecast by Market Taxonomy 17.7.2.2.1. By Indication 17.7.2.2.2. By Diagnosis & Treatment Type 17.7.2.2.3. By Distribution Channel 17.7.2.2.4. By Service Providers 17.7.3. South Korea Market 17.7.3.1. Introduction 17.7.3.2. Market Analysis and Forecast by Market Taxonomy 17.7.3.2.1. By Indication 17.7.3.2.2. By Diagnosis & Treatment Type 17.7.3.2.3. By Distribution Channel 17.7.3.2.4. By Service Providers 18. Oceania Market Analysis 2012 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2022 18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. Australia 18.3.1.2. New Zealand 18.3.2. By Indication 18.3.3. By Diagnosis & Treatment Type 18.3.4. By Distribution Channel 18.3.5. By Service Providers 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Indication 18.4.3. By Diagnosis & Treatment Type 18.4.4. By Distribution Channel 18.4.5. By Service Providers 18.5. Key Market Participants - Intensity Mapping 18.6. Drivers and Restraints - Impact Analysis 18.7. Country Level Analysis & Forecast 18.7.1. Australia Market 18.7.1.1. Introduction 18.7.1.2. Market Analysis and Forecast by Market Taxonomy 18.7.1.2.1. By Indication 18.7.1.2.2. By Diagnosis & Treatment Type 18.7.1.2.3. By Distribution Channel 18.7.1.2.4. By Service Providers 18.7.2. New Zealand Market 18.7.2.1. Introduction 18.7.2.2. Market Analysis and Forecast by Market Taxonomy 18.7.2.2.1. By Indication 18.7.2.2.2. By Diagnosis & Treatment Type 18.7.2.2.3. By Distribution Channel 18.7.2.2.4. By Service Providers 19. Middle East & Africa Market Analysis 2012 to 2022and Forecast 2023 to 2033 19.1. Introduction 19.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2022 19.3. Current and Future Market Size (US$ Million)Analysis and Forecast By Market Taxonomy, 2023 to 2033 19.3.1. By Country 19.3.1.1. GCC Countries 19.3.1.2. Türkiye 19.3.1.3. South Africa 19.3.1.4. North Africa 19.3.1.5. Rest of MEA 19.3.2. By Indication 19.3.3. By Diagnosis & Treatment Type 19.3.4. By Distribution Channel 19.3.5. By Service Providers 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Indication 19.4.3. By Diagnosis & Treatment Type 19.4.4. By Distribution Channel 19.4.5. By Service Providers 19.5. Key Market Participants - Intensity Mapping 19.6. Drivers and Restraints - Impact Analysis 19.7. Country Level Analysis & Forecast 19.7.1. GCC Countries Market 19.7.1.1. Introduction 19.7.1.2. Market Analysis and Forecast by Market Taxonomy 19.7.1.2.1. By Indication 19.7.1.2.2. By Diagnosis & Treatment Type 19.7.1.2.3. By Distribution Channel 19.7.1.2.4. By Service Providers 19.7.2. Türkiye Market 19.7.2.1. Introduction 19.7.2.2. Market Analysis and Forecast by Market Taxonomy 19.7.2.2.1. By Indication 19.7.2.2.2. By Diagnosis & Treatment Type 19.7.2.2.3. By Distribution Channel 19.7.2.2.4. By Service Providers 19.7.3. South Africa Market 19.7.3.1. Introduction 19.7.3.2. Market Analysis and Forecast by Market Taxonomy 19.7.3.2.1. By Indication 19.7.3.2.2. By Diagnosis & Treatment Type 19.7.3.2.3. By Distribution Channel 19.7.3.2.4. By Service Providers 19.7.4. North Africa Market 19.7.4.1. Introduction 19.7.4.2. Market Analysis and Forecast by Market Taxonomy 19.7.4.2.1. By Indication 19.7.4.2.2. By Diagnosis & Treatment Type 19.7.4.2.3. By Distribution Channel 19.7.4.2.4. By Service Providers 20. Competition Analysis 20.1. Competition Dashboard 20.2. Competition Benchmarking 20.3. Competition Deep Dive 20.3.1. Medtronic Plc 20.3.1.1. Overview 20.3.1.2. Product Portfolio 20.3.1.3. Key Financial 20.3.1.4. Sales Footprint 20.3.1.5. SWOT Analysis 20.3.1.6. Key Developments 20.3.1.7. Strategy Overview 20.3.1.7.1. Marketing Strategies 20.3.1.7.2. Product Strategies 20.3.1.7.3. Channel Strategies 20.3.2. Piramal Enterprises Ltd. 20.3.2.1. Overview 20.3.2.2. Product Portfolio 20.3.2.3. Key Financial 20.3.2.4. Sales Footprint 20.3.2.5. SWOT Analysis 20.3.2.6. Key Developments 20.3.2.7. Strategy Overview 20.3.2.7.1. Marketing Strategies 20.3.2.7.2. Product Strategies 20.3.2.7.3. Channel Strategies 20.3.3. AbbVie, Inc. (Allergan) 20.3.3.1. Overview 20.3.3.2. Product Portfolio 20.3.3.3. Key Financial 20.3.3.4. Sales Footprint 20.3.3.5. SWOT Analysis 20.3.3.6. Key Developments 20.3.3.7. Strategy Overview 20.3.3.7.1. Marketing Strategies 20.3.3.7.2. Product Strategies 20.3.3.7.3. Channel Strategies 20.3.4. Ipsen Pharma 20.3.4.1. Overview 20.3.4.2. Product Portfolio 20.3.4.3. Key Financial 20.3.4.4. Sales Footprint 20.3.4.5. SWOT Analysis 20.3.4.6. Key Developments 20.3.4.7. Strategy Overview 20.3.4.7.1. Marketing Strategies 20.3.4.7.2. Product Strategies 20.3.4.7.3. Channel Strategies 20.3.5. F. Hoffmann-La Roche Ltd 20.3.5.1. Overview 20.3.5.2. Product Portfolio 20.3.5.3. Key Financial 20.3.5.4. Sales Footprint 20.3.5.5. SWOT Analysis 20.3.5.6. Key Developments 20.3.5.7. Strategy Overview 20.3.5.7.1. Marketing Strategies 20.3.5.7.2. Product Strategies 20.3.5.7.3. Channel Strategies 20.3.6. GlaxoSmithKline plc 20.3.6.1. Overview 20.3.6.2. Product Portfolio 20.3.6.3. Key Financial 20.3.6.4. Sales Footprint 20.3.6.5. SWOT Analysis 20.3.6.6. Key Developments 20.3.6.7. Strategy Overview 20.3.6.7.1. Marketing Strategies 20.3.6.7.2. Product Strategies 20.3.6.7.3. Channel Strategies 20.3.7. Pfizer Inc. 20.3.7.1. Overview 20.3.7.2. Product Portfolio 20.3.7.3. Key Financial 20.3.7.4. Sales Footprint 20.3.7.5. SWOT Analysis 20.3.7.6. Key Developments 20.3.7.7. Strategy Overview 20.3.7.7.1. Marketing Strategies 20.3.7.7.2. Product Strategies 20.3.7.7.3. Channel Strategies 20.3.8. Elite Pharmaceuticals Inc. 20.3.8.1. Overview 20.3.8.2. Product Portfolio 20.3.8.3. Key Financial 20.3.8.4. Sales Footprint 20.3.8.5. SWOT Analysis 20.3.8.6. Key Developments 20.3.8.7. Strategy Overview 20.3.8.7.1. Marketing Strategies 20.3.8.7.2. Product Strategies 20.3.8.7.3. Channel Strategies 20.3.9. Orient Pharma 20.3.9.1. Overview 20.3.9.2. Product Portfolio 20.3.9.3. Key Financial 20.3.9.4. Sales Footprint 20.3.9.5. SWOT Analysis 20.3.9.6. Key Developments 20.3.9.7. Strategy Overview 20.3.9.7.1. Marketing Strategies 20.3.9.7.2. Product Strategies 20.3.9.7.3. Channel Strategies 20.3.10. Acorda Therapeutics, Inc. 20.3.10.1. Overview 20.3.10.2. Product Portfolio 20.3.10.3. Key Financial 20.3.10.4. Sales Footprint 20.3.10.5. SWOT Analysis 20.3.10.6. Key Developments 20.3.10.7. Strategy Overview 20.3.10.7.1. Marketing Strategies 20.3.10.7.2. Product Strategies 20.3.10.7.3. Channel Strategies 20.3.11. Sun Pharmaceutical Industries Ltd 20.3.11.1. Overview 20.3.11.2. Product Portfolio 20.3.11.3. Key Financial 20.3.11.4. Sales Footprint 20.3.11.5. SWOT Analysis 20.3.11.6. Key Developments 20.3.11.7. Strategy Overview 20.3.11.7.1. Marketing Strategies 20.3.11.7.2. Product Strategies 20.3.11.7.3. Channel Strategies 20.3.12. Novartis AG (Alcon) 20.3.12.1. Overview 20.3.12.2. Product Portfolio 20.3.12.3. Key Financial 20.3.12.4. Sales Footprint 20.3.12.5. SWOT Analysis 20.3.12.6. Key Developments 20.3.12.7. Strategy Overview 20.3.12.7.1. Marketing Strategies 20.3.12.7.2. Product Strategies 20.3.12.7.3. Channel Strategies 20.3.13. Teva Pharmaceutical Industries Ltd 20.3.13.1. Overview 20.3.13.2. Product Portfolio 20.3.13.3. Key Financial 20.3.13.4. Sales Footprint 20.3.13.5. SWOT Analysis 20.3.13.6. Key Developments 20.3.13.7. Strategy Overview 20.3.13.7.1. Marketing Strategies 20.3.13.7.2. Product Strategies 20.3.13.7.3. Channel Strategies 20.3.14. Zydus Cadila Healthcare Ltd. 20.3.14.1. Overview 20.3.14.2. Product Portfolio 20.3.14.3. Key Financial 20.3.14.4. Sales Footprint 20.3.14.5. SWOT Analysis 20.3.14.6. Key Developments 20.3.14.7. Strategy Overview 20.3.14.7.1. Marketing Strategies 20.3.14.7.2. Product Strategies 20.3.14.7.3. Channel Strategies 20.3.15. Beximco Pharmaceuticals Ltd 20.3.15.1. Overview 20.3.15.2. Product Portfolio 20.3.15.3. Key Financial 20.3.15.4. Sales Footprint 20.3.15.5. SWOT Analysis 20.3.15.6. Key Developments 20.3.15.7. Strategy Overview 20.3.15.7.1. Marketing Strategies 20.3.15.7.2. Product Strategies 20.3.15.7.3. Channel Strategies 20.3.16. Merz Pharma 20.3.16.1. Overview 20.3.16.2. Product Portfolio 20.3.16.3. Key Financial 20.3.16.4. Sales Footprint 20.3.16.5. SWOT Analysis 20.3.16.6. Key Developments 20.3.16.7. Strategy Overview 20.3.16.7.1. Marketing Strategies 20.3.16.7.2. Product Strategies 20.3.16.7.3. Channel Strategies 20.3.17. Thought Technology Ltd. 20.3.17.1. Overview 20.3.17.2. Product Portfolio 20.3.17.3. Key Financial 20.3.17.4. Sales Footprint 20.3.17.5. SWOT Analysis 20.3.17.6. Key Developments 20.3.17.7. Strategy Overview 20.3.17.7.1. Marketing Strategies 20.3.17.7.2. Product Strategies 20.3.17.7.3. Channel Strategies 20.3.18. UltraCare PRO 20.3.18.1. Overview 20.3.18.2. Product Portfolio 20.3.18.3. Key Financial 20.3.18.4. Sales Footprint 20.3.18.5. SWOT Analysis 20.3.18.6. Key Developments 20.3.18.7. Strategy Overview 20.3.18.7.1. Marketing Strategies 20.3.18.7.2. Product Strategies 20.3.18.7.3. Channel Strategies 20.3.19. Invacare Corporation 20.3.19.1. Overview 20.3.19.2. Product Portfolio 20.3.19.3. Key Financial 20.3.19.4. Sales Footprint 20.3.19.5. SWOT Analysis 20.3.19.6. Key Developments 20.3.19.7. Strategy Overview 20.3.19.7.1. Marketing Strategies 20.3.19.7.2. Product Strategies 20.3.19.7.3. Channel Strategies 20.3.20. ATI Physical Therapy 20.3.20.1. Overview 20.3.20.2. Product Portfolio 20.3.20.3. Key Financial 20.3.20.4. Sales Footprint 20.3.20.5. SWOT Analysis 20.3.20.6. Key Developments 20.3.20.7. Strategy Overview 20.3.20.7.1. Marketing Strategies 20.3.20.7.2. Product Strategies 20.3.20.7.3. Channel Strategies 20.3.21. P.T. Services Rehabilitation, Inc. 20.3.21.1. Overview 20.3.21.2. Product Portfolio 20.3.21.3. Key Financial 20.3.21.4. Sales Footprint 20.3.21.5. SWOT Analysis 20.3.21.6. Key Developments 20.3.21.7. Strategy Overview 20.3.21.7.1. Marketing Strategies 20.3.21.7.2. Product Strategies 20.3.21.7.3. Channel Strategies 20.3.22. Banner Health 20.3.22.1. Overview 20.3.22.2. Product Portfolio 20.3.22.3. Key Financial 20.3.22.4. Sales Footprint 20.3.22.5. SWOT Analysis 20.3.22.6. Key Developments 20.3.22.7. Strategy Overview 20.3.22.7.1. Marketing Strategies 20.3.22.7.2. Product Strategies 20.3.22.7.3. Channel Strategies 21. Assumptions and Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports
Spasticity Treatment Market
